A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis

Homologous recombination deficiency (HRD) has become an important prognostic and predictive biomarker for patients with high-grade serous ovarian cancer who may benefit from poly-ADP ribose polymerase inhibitors (PARPi) and platinum-based therapies. HRD testing provides relevant information to perso...

Full description

Bibliographic Details
Main Authors: Rodrigo Guarischi-Sousa, José Eduardo Kroll, Adriano Bonaldi, Paulo Marques Pierry, Darine Villela, Camila Alves Souza, Juliana Santos Silva, Matheus Carvalho Bürger, Felipe Azevedo Oliveira, Marcelo Gomes de Paula, Fabiana Marcelino Meliso, Luiz Gustavo de Almeida, Priscilla Morais Monfredini, Ana Gabriela de Oliveira, Fernanda Milanezi, Cristovam Scapulatempo-Neto, Guilherme Lopes Yamamoto
Format: Article
Language:English
Published: MDPI AG 2023-10-01
Series:Diagnostics
Subjects:
homologous recombination deficiency (HRD)
biomarkers
ovarian cancer
DNA repair
<i>BRCA1</i>/<i>2</i>
poly (ADP–ribose) (PARP) inhibitors (PARPi)
Online Access:https://www.mdpi.com/2075-4418/13/21/3293

Internet

https://www.mdpi.com/2075-4418/13/21/3293

Similar Items